Portal de Periódicos da CAPES

Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort

2014; BMJ; Volume: 74; Issue: 8 Linguagem: Inglês

10.1136/annrheumdis-2013-203933

1468-2060

Ben Parker, Murray B. Urowitz, Dafna D. Gladman, Mark Lunt, Rachelle Donn, Sang‐Cheol Bae, Jorge Sánchez‐Guerrero, Juanita Romero‐Díaz, Caroline Gordon, Daniel J. Wallace, Ann E. Clarke, Sasha Bernatsky, Ellen M. Ginzler, David Isenberg, Anisur Rahman, Joan T. Merrill, Graciela S. Alarcón, Barri J. Fessler, Paul R. Fortin, John G. Hanly, Michelle Petri, Kristján Steinsson, Mary Anne Dooley, Susan Manzi, Munther A. Khamashta, Rosalind Ramsey‐Goldman, Asad Zoma, Gunnar Sturfelt, Ola Nived, Cynthia Aranow, Meggan Mackay, Manuel Ramos‐Casals, Ronald van Vollenhoven, Kenneth Kalunian, Guillermo Ruiz‐Irastorza, S. Sam Lim, Diane L. Kamen, Christine A. Peschken, Murat İnanç, Ian N Bruce,

Lipid metabolism and disorders

The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.Recently diagnosed ( 1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort.MetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course.